These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36013149)

  • 1. The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores-An 11.6-Year Follow-Up Study.
    Sandvik ECS; Aasarød KM; Johnsen G; Hoff DAL; Kulseng B; Hyldmo ÅA; Græslie H; Nymo S; Sandvik J; Fossmark R
    J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of magnetic resonance elastography (MRE) to biomarker testing for staging fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Kaplan JM; Alexis J; Grimaldi G; Islam M; Izard SM; Lee TP
    Transl Gastroenterol Hepatol; 2023; 8():7. PubMed ID: 36704653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced liver fibrosis and the metabolic syndrome in a primary care setting.
    Schreiner AD; Zhang J; Durkalski-Mauldin V; Livingston S; Marsden J; Bian J; Mauldin PD; Moran WP; Rockey DC
    Diabetes Metab Res Rev; 2021 Nov; 37(8):e3452. PubMed ID: 33759300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-invasive fibrosis assessments of non-alcoholic fatty liver disease associated with low estimated glomerular filtration rate among CKD patients: the Fukuoka Kidney disease Registry Study.
    Hara M; Tanaka S; Torisu K; Matsukuma Y; Tsuchimoto A; Tokumoto M; Ooboshi H; Nakano T; Tsuruya K; Kitazono T
    Clin Exp Nephrol; 2021 Aug; 25(8):822-834. PubMed ID: 33856608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients.
    Wang Z; Wang Y; Luo F; Zhai Y; Li J; Chen Y; Li Q; Zhu L; Jiao S; Liu P; Zhou Y; Chen Y; Dong J; Sun Y
    Front Cardiovasc Med; 2022; 9():960259. PubMed ID: 36277780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.
    Kang MK; Kim MC
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837575
    [No Abstract]   [Full Text] [Related]  

  • 7. Trajectory of NAFLD characteristics after Roux-en-Y gastric bypass: a five-year historical cohort study.
    Kreve F; Callejas GH; Jimenez LS; Marques RA; Chaim FDM; Utrini MP; Gestic MA; Ramos AC; Chaim EA; Cazzo E
    Sao Paulo Med J; 2022; 140(6):739-746. PubMed ID: 36102453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.
    McPherson S; Hardy T; Dufour JF; Petta S; Romero-Gomez M; Allison M; Oliveira CP; Francque S; Van Gaal L; Schattenberg JM; Tiniakos D; Burt A; Bugianesi E; Ratziu V; Day CP; Anstee QM
    Am J Gastroenterol; 2017 May; 112(5):740-751. PubMed ID: 27725647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
    Huang C; Seah JJ; Tan CK; Kam JW; Tan J; Teo EK; Kwek A; Wong YJ; Tan M; Ang TL; Kumar R
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101528. PubMed ID: 33268036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of sleeve gastrectomy and Roux-en-Y gastric bypass on biopsy-proven non-alcoholic fatty liver disease.
    Cherla DV; Rodriguez NA; Vangoitsenhoven R; Singh T; Mehta N; McCullough AJ; Brethauer SA; Schauer PR; Aminian A
    Surg Endosc; 2020 May; 34(5):2266-2272. PubMed ID: 31359195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores.
    Patel PJ; Cheng JC; Banh X; Gracen L; Radford-Smith D; Hossain F; Horsfall LU; Hayward KL; Williams S; Johnson T; Brown NN; Saad N; Stuart KA; Russell AW; Valery PC; Clouston AD; Irvine KM; Bernard A; Powell EE
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):710-718.e4. PubMed ID: 31352092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications.
    Takahashi Y; Kurosaki M; Tamaki N; Yasui Y; Hosokawa T; Tsuchiya K; Nakanishi H; Itakura J; Izumi N
    Hepatol Res; 2015 Jun; 45(6):667-75. PubMed ID: 25145976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLD.
    Torres L; Schuch A; Longo L; Valentini BB; Galvão GS; Luchese E; Pinzon C; Bartels R; Álvares-da-Silva MR
    Ann Hepatol; 2023; 28(1):100774. PubMed ID: 36280013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity.
    Drolz A; Wolter S; Wehmeyer MH; Piecha F; Horvatits T; Schulze Zur Wiesch J; Lohse AW; Mann O; Kluwe J
    Int J Obes (Lond); 2021 Oct; 45(10):2197-2204. PubMed ID: 34168277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies.
    Pedersen JS; Rygg MO; Serizawa RR; Kristiansen VB; Albrechtsen NJW; Gluud LL; Madsbad S; Bendtsen F
    J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
    Kjaergaard M; Lindvig KP; Thorhauge KH; Andersen P; Hansen JK; Kastrup N; Jensen JM; Hansen CD; Johansen S; Israelsen M; Torp N; Trelle MB; Shan S; Detlefsen S; Antonsen S; Andersen JE; Graupera I; Ginés P; Thiele M; Krag A
    J Hepatol; 2023 Aug; 79(2):277-286. PubMed ID: 37088311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era.
    Park H; Yoon EL; Kim M; Lee J; Kim JH; Cho S; Jun DW; Nah EH
    Hepatol Res; 2022 Mar; 52(3):247-254. PubMed ID: 34841632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study.
    Froylich D; Corcelles R; Daigle C; Boules M; Brethauer S; Schauer P
    Surg Obes Relat Dis; 2016 Jan; 12(1):127-31. PubMed ID: 26077701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study.
    Tan EX; Lee JW; Jumat NH; Chan WK; Treeprasertsuk S; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Lesmana LA; Zheng KI; Zheng MH; Koh CJ; Ho KY; Goh KL; Wong VW; Dan YY
    Metabolism; 2022 Jan; 126():154911. PubMed ID: 34648769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.